

Rational Design of ROS-Responsive Nanocarriers for Targeted X-ray-Induced Photodynamic Therapy and Cascaded Chemotherapy of Intracranial Glioblastoma

Beibei Zhang[†], Rui Xue[†], Chunyang Sun^{†,‡,*}

[†] Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China

[‡] Multimodality Preclinical Molecular Imaging Center, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China

E-mail: chysunshine@gmail.com (C. Y. Sun)




Figure S1. Synthetic routes for TK linker, PEG-TK-PTX, PEG-PTX and Ang-PEG-DSPE, respectively.




Figure S2. ^1H NMR spectrum of PEG-TK-PTX.




Figure S3. ^1H NMR spectrum of PEG-PTX.




Figure S4. ¹H NMR spectrum of Mal-PEG-DSPE and Ang-PEG-DSPE.




Figure S5. Particle size changes before and after 4 Gy of X-ray exposure.




Figure S6. TEM images of $^{TK}NP_{VP}$, $T-NP_{VP}$ and $T-TKNP_{VP}$ after 4 Gy of X-ray irradiation.




Figure S7. ¹H NMR spectra of ^{TK}NP_{VP}, T-NP_{VP} and T-^{TK}NP_{VP} before and after 4 Gy of X-ray exposure.




Figure S8. The viabilities of bEnd.3 cells after incubation with $^{TK}NP_{VP}$, $T-NP_{VP}$ or $T-TKNP_{VP}$ at different PTX concentrations for 24 h.




Figure S9. (A) Fluorescence distribution of $T-TKNP_{ICG}$ in isolated organs at 6, 8 and 12 h post-injection. (B) Fluorescence distribution of $^{TK}NP_{ICG}$, $T-NP_{ICG}$ or $T-TKNP_{ICG}$ in major organs at 24 h post-injection ($n = 3$).




Figure S10. Body weight changes after treatment with various formulations.

Table S1. Diameter and zeta potential of $^{TK}NP_{VP}$, T-NP_{VP} and T- $^{TK}NP_{VP}$.

	diamter (nm)	polydispersity	zeta potential (mV)
$^{TK}NP_{VP}$	50.17±2.90	0.124	-11.8
T-NP _{VP}	52.83±2.72	0.133	-13.9
T- $^{TK}NP_{VP}$	52.33±4.12	0.147	-13.5

Table S2. Drug loading content (DLC) and encapsulation efficiency (EE) of $^{TK}NP_{VP}$, T-NP_{VP} and T- $^{TK}NP_{VP}$.

	DLC (%)		EE (%)	
	PTX	VP	PTX	VP
$^{TK}NP_{VP}$	20.34±1.36	8.46±0.62	78.10±5.24	81.17±5.95
T-NP _{VP}	21.04±1.77	8.79±0.39	76.01±6.40	79.33±3.52
T- $^{TK}NP_{VP}$	19.25±1.12	9.25±0.43	68.99±4.01	82.86±3.88

Table S3. Animal number and their body weight (unit: g) during treatment.

Days	16	20	24	28	32	36
PBS	7(19.46±0.7)8	7(18.54±1.89)	6(17.53±1.38)	3(15.46±1.30)	1(14.5)	0
PTX+VP	7(20.24±0.38)	7(19.54±0.79)	6(18.75±0.97)	4(17.02±0.60)	2(14.95±0.65)	0
T- ^{TK} NP _{VP}	7(18.54±0.8)	7(18.54±0.48)	7(18.24±0.40)	6(16.74±0.39)	0	0
PBS(+)	7(19.33±0.42)	7(18.54±0.73)	7(18.33±0.43)	7(17.33±0.42)	6(16.25±0.95)	4(15.5±0.35)
^{TK} NP _{VP} (+)	7(19.49±0.78)	7(19.24±1.19)	7(19.24±0.73)	7(19.74±0.75)	7(19.16±0.47)	6(15.5±0.71)
T-NP _{VP} (+)	7(19.56±1.81)	7(20.84±1.97)	7(21.17±2.15)	7(20.56±1.24)	7(20.43±0.42)	7(19.79±0.88)
T- ^{TK} NP _{VP} (+)	7(19.64±0.85)	7(19.54±1.38)	7(20.44±1.11)	7(20.44±0.83)	7(20.21±0.59)	7(19.5±0.76)

Days	40	44	48	52	56	60
PBS						
PTX+VP						
T- ^{TK} NP _{VP}						
PBS(+)	0					
^{TK} NP _{VP} (+)	2(14±0.71)	0				
T-NP _{VP} (+)	7(19.43±0.68)	7(20.63±0.88)	2(15.17±0.62)	1(14)	0	
T- ^{TK} NP _{VP} (+)	7(19.36±0.64)	7(18.36±0.91)	6(17.75±1.18)	3(15.38±0.65)	1(15)	0

Table S4. Routine blood test of ^{TK}NP_{VP}, T-NP_{VP} and T-^{TK}NP_{VP}.

	PTX+VP	^{TK} NP _{VP}	T-NP _{VP}	T- ^{TK} NP _{VP}	Unit
WBC	3.86±0.94	5.12±0.38	6.4±0.88	7.01±0.81	10 ⁹ /L
RBC	11.3±0.58	11.18±0.36	11.5±0.52	11.83±0.38	10 ¹² /L
Hb	155.25±6.1	152.75±4.21	156.75±4.76	158.25±4.55	g/L
HCT	38.93±1.22	38.3±0.61	38.98±1.06	39.9±1.42	L/L
MCV	34.45±1	34.3±0.86	33.93±0.54	33.85±1.31	fL
MCH	13.75±0.32	13.68±0.36	13.68±0.25	13.43±0.55	pg
MCHC	398.75±6.98	398.75±5.4	402.25±4.82	396.75±13.94	g/L